316 related articles for article (PubMed ID: 21147120)
1. Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure.
Iwata M; Cowling RT; Yeo SJ; Greenberg B
J Mol Cell Cardiol; 2011 Oct; 51(4):542-7. PubMed ID: 21147120
[TBL] [Abstract][Full Text] [Related]
2. ACE2 of the heart: From angiotensin I to angiotensin (1-7).
Keidar S; Kaplan M; Gamliel-Lazarovich A
Cardiovasc Res; 2007 Feb; 73(3):463-9. PubMed ID: 17049503
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart.
Mercure C; Yogi A; Callera GE; Aranha AB; Bader M; Ferreira AJ; Santos RA; Walther T; Touyz RM; Reudelhuber TL
Circ Res; 2008 Nov; 103(11):1319-26. PubMed ID: 18845809
[TBL] [Abstract][Full Text] [Related]
4. Aerobic exercise training-induced left ventricular hypertrophy involves regulatory MicroRNAs, decreased angiotensin-converting enzyme-angiotensin ii, and synergistic regulation of angiotensin-converting enzyme 2-angiotensin (1-7).
Fernandes T; Hashimoto NY; Magalhães FC; Fernandes FB; Casarini DE; Carmona AK; Krieger JE; Phillips MI; Oliveira EM
Hypertension; 2011 Aug; 58(2):182-9. PubMed ID: 21709209
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice.
Patel VB; Bodiga S; Fan D; Das SK; Wang Z; Wang W; Basu R; Zhong J; Kassiri Z; Oudit GY
Hypertension; 2012 Jun; 59(6):1195-203. PubMed ID: 22508831
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme 2 as a therapeutic target for heart failure.
Chamsi-Pasha MA; Shao Z; Tang WH
Curr Heart Fail Rep; 2014 Mar; 11(1):58-63. PubMed ID: 24293035
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme 2-Angiotensin 1-7/1-9 system: novel promising targets for heart failure treatment.
Kittana N
Fundam Clin Pharmacol; 2018 Feb; 32(1):14-25. PubMed ID: 28833476
[TBL] [Abstract][Full Text] [Related]
8. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7).
Grobe JL; Mecca AP; Lingis M; Shenoy V; Bolton TA; Machado JM; Speth RC; Raizada MK; Katovich MJ
Am J Physiol Heart Circ Physiol; 2007 Feb; 292(2):H736-42. PubMed ID: 17098828
[TBL] [Abstract][Full Text] [Related]
9. Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure.
Mori J; Zhang L; Oudit GY; Lopaschuk GD
J Mol Cell Cardiol; 2013 Oct; 63():98-106. PubMed ID: 23886814
[TBL] [Abstract][Full Text] [Related]
10. [Regulation of angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis provides a new target for the treatment of cardiac remodeling and heart failure].
Yang L; Huang Y; He Q
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Nov; 31(11):1425-1428. PubMed ID: 31898578
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy.
Oudit GY; Penninger JM
Curr Heart Fail Rep; 2011 Sep; 8(3):176-83. PubMed ID: 21611889
[TBL] [Abstract][Full Text] [Related]
12. The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction.
Wang J; He W; Guo L; Zhang Y; Li H; Han S; Shen D
Mol Med Rep; 2017 Aug; 16(2):1973-1981. PubMed ID: 28656296
[TBL] [Abstract][Full Text] [Related]
13. Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats.
Trask AJ; Averill DB; Ganten D; Chappell MC; Ferrario CM
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H3019-24. PubMed ID: 17308000
[TBL] [Abstract][Full Text] [Related]
14. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension.
Mendoza-Torres E; Oyarzún A; Mondaca-Ruff D; Azocar A; Castro PF; Jalil JE; Chiong M; Lavandero S; Ocaranza MP
Ther Adv Cardiovasc Dis; 2015 Aug; 9(4):217-37. PubMed ID: 26275770
[TBL] [Abstract][Full Text] [Related]
15. Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.
Reyes S; Varagic J; Ahmad S; VonCannon J; Kon ND; Wang H; Groban L; Cheng CP; Dell'Italia LJ; Ferrario CM
Curr Hypertens Rep; 2017 Feb; 19(2):16. PubMed ID: 28233239
[TBL] [Abstract][Full Text] [Related]
16. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction.
Kassiri Z; Zhong J; Guo D; Basu R; Wang X; Liu PP; Scholey JW; Penninger JM; Oudit GY
Circ Heart Fail; 2009 Sep; 2(5):446-55. PubMed ID: 19808375
[TBL] [Abstract][Full Text] [Related]
17. ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis.
Simões E Silva AC; Teixeira MM
Pharmacol Res; 2016 May; 107():154-162. PubMed ID: 26995300
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS.
Patel VB; Clarke N; Wang Z; Fan D; Parajuli N; Basu R; Putko B; Kassiri Z; Turner AJ; Oudit GY
J Mol Cell Cardiol; 2014 Jan; 66():167-76. PubMed ID: 24332999
[TBL] [Abstract][Full Text] [Related]
19. Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart.
Garabelli PJ; Modrall JG; Penninger JM; Ferrario CM; Chappell MC
Exp Physiol; 2008 May; 93(5):613-21. PubMed ID: 18356559
[TBL] [Abstract][Full Text] [Related]
20. ACE2/Ang-(1-7) signaling and vascular remodeling.
Zhang Z; Chen L; Zhong J; Gao P; Oudit GY
Sci China Life Sci; 2014 Aug; 57(8):802-8. PubMed ID: 25104453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
